These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Metabolic profiles and pharmacokinetics of picroside I in rats by liquid chromatography combined with electrospray ionization tandem mass spectrometry.
    Author: Xiong K, Ju Z, Zhang T, Wang Z, Han H.
    Journal: J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Sep 15; 1095():157-165. PubMed ID: 30077096.
    Abstract:
    Picroside I is an iridoid glycoside derived from Picrorhiza kurroa Royle ex Benth and Picrorhiza scrophulariiflora Pennell and characterized by many biological activities. In this study, a fast, selective, and sensitive UHPLC-MS/MS method was developed and validated to determine picroside I in rat plasma. Analytes were separated by using an ACQUITY UPLC® BEH C18 (2.1 × 50 mm, 1.7 μm) column at a running time of 2 min. Selected reaction monitoring (SRM) transitions were m/z 491.1 → 147.1 for picroside I and m/z 511.1 → 235.1 for the internal standard in a negative ion mode. The established UHPLC-MS/MS method achieved good linearity for picroside I within the range of 0.1-500 ng/mL. The validated method was successfully applied for the pharmacokinetic analysis of picroside I in rats after oral administration. Fifteen metabolites of picroside I were tentatively identified through ultra-high-performance chromatography/tandem quadrupole time-of-flight mass spectrometry, and four metabolites were identified by comparing with the standards. Besides, nine of these metabolites were discovered for the first time. The proposed metabolic pathways of picroside I in vivo can be divided into four parts, namely, phase I reaction of picroside I, including hydroxylation and deoxygenation; phase II reaction of picroside I, including glucuronidation, sulfation, and methylation; phase I biotransformations of metabolites, such as reduction and hydroxylation; and phase II biotransformations of metabolites, such as glucuronidation and sulfation. These results could offer insights into the effectiveness and toxicity of picroside I.
    [Abstract] [Full Text] [Related] [New Search]